Ensure Seamless Clinical Trial Transition Across Global Markets

By Alex Kavros, Executive Vice President, Scientific & Regulatory Affairs

To ensure rapid access to life-saving therapeutics, drug sponsors are exploring new strategies to execute clinical trials as efficiently and rapidly as possible. As clinical development becomes an increasingly global enterprise and drug sponsors aim to reach global markets, many U.S., Asian, and European biotechs are considering the potential of conducting early-phase trials abroad. Australia has become an appealing destination thanks to its rapid pathways to trial, R&D tax incentives, and world-class research infrastructure. Many sponsors are considering the possibilities of beginning early-phase trials in Australia and then transitioning late-phase trials to the U.S.

Though the logistics of transitioning a trial from country to country may initially seem daunting, there are well-honed pathways available that ensure seamless transition and continuous regulatory compliancefrom country to country. If your team is considering whether this strategy might benefit your trial, download the full article to explore the options available to you, including working with a CRO that offers well-honed workflows for tackling multi-regional clinical trials.

This was validated in 2024.